İbrahim GÜNDOĞMUŞ, Mikail Burak AYDIN, Yasemin ERKEN, Ayşegül TAŞDELEN KUL

Severe acute urinary retention requiring urinary catheterization in a young female patient using duloxetine: A case report

Side effects are one of the most important obstacles to the use of psychotropic drugs. Although duloxetine, commonly used in clinicalpractice, is known to be an effective and reliable antidepressant, it is known to cause some side effects. Although it has been reportedin the literature that urinary side effects such as urination difficulties and frequent urination may be encountered, especially in men,it is very rare in women. Urinary retention is defined that is sudden onset of inability to void or presence of important amount ofpostmicturitional residual urine. It has been reported that drug-induced urinary retention may be associated with psychotropic drugssuch as olanzapine, sertraline, aripiprazole and duloxetine in the literature. The cases associated with duloxetine were generally seenin combination form and with organic pathologies. As far as we know, the young female patient who has no organic pathology has nourinary retention associated with the use of duloxetine. In this report, we present a young female patient who had a 32-year-old withoutorganic disease who developed urinary retention requiring urinary catheterization after the use of duloxetine.

PDF

___

1. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-6.
2. Van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG. 2004;111:249-57.
3. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15.
4. Gundogmus I, Ispir M, Algul A, et al. Duloxetineinduced ejaculation with defacation: a case report. Anatolian J Psychiatry 2017;18:404-7.
5. Wang SM, Lee KU, Jeon YW, et al. Severe urinary retention requiring urinary catheterization associated with combined treatment of depression with duloxetine and quetiapine. Psychiatry Clin Neurosci 2013;67:191.
6. Klarskov P, Andersen JT, Asmussen CF, et al. Acute urinary retention in women: a prospective study of 18 consecutive cases. Scand J Urol Nephrol 1987;21:29-31.
7. Teo R, Punter J, Abrams K, et al. Clinically overt postpartum urinary retention after vaginal delivery: a retrospective case-control study. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:521-4.
8. Goodwin RJ, Swinn MJ, Fowler CJ. The neurophysiology of urinary retention in young women and its treatment by neuromodulation. World J Urol 1998;16:305-7.
9. Lowenstein L, Mueller ER, Sharma S, et al. Urinary hesitancy and retention during treatment with sertraline. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:827-9.
10. Verhamme KM, Sturkenboom MC, Stricker BH, et al. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008;31:373- 88.
11. Cohen R, Wilkins KM, Ostroff R, et al. Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother 2007;5:241-6.
12. Hsu WY, Chang TG, Chiu NY. Aripiprazole associated urine retention in a male schizophrenia patient.Gen Hosp Psychiatry 2013;35:680.11-2.
13. Englisch S, Fritzinger M, Zink M. Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine. Clin Neuropharmacol 2008;31:307-9.
14. Aktürk Esen S, Gül CB, Kahvecioğlu S, et al. Acute urinary retention and acute kidney injury after duloxetine treatment: A Rare Case Report. J Clin Psychopharmacol 2019;39:279-81.
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
16. Stahl SM. Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology. CNS Spectr 2008;13:115-8.
17. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 2003;62:3-9.
18. Espey MJ, Du HJ, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 1998;6;798:101-8.
19. Viktrup L, Pangallo BA, Detke MJ, et al. Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence. Prim Care Companion J Clin Psychiatry 2004;6:65-73.
20. Claghorn JL, Earl CQ, Walczak DD, et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113-20.
21. Benazzi F. Urinary retention with venlafaxine‐fluoxetine combination. Hum Psychopharmacol 1998;13:139- 40.
22. Gundogmus I, Ispir M, Bakkal O, et al. Venlafaxineinduced prostatism: a case report. Psychiatry and Clin Psychopharmacol 2017:1-2.
23. Holm KJ, Spencer CM. Reboxetine. CNS drugs 1999;12:65-83.